Literature DB >> 22698564

Risk factors for 1-year mortality after thoracic endovascular aortic repair.

Asad A Shah1, Damian M Craig, Nicholas D Andersen, Judson B Williams, Syamal D Bhattacharya, Svati H Shah, Richard L McCann, G Chad Hughes.   

Abstract

OBJECTIVE: Thoracic endovascular aortic repair, although physiologically well tolerated, may fail to confer significant survival benefit in some high-risk patients. In an effort to identify patients most likely to benefit from intervention, the present study sought to determine the risk factors for 1-year mortality after thoracic endovascular aortic repair.
METHODS: A retrospective review was performed on prospectively collected data from all patients undergoing thoracic endovascular aortic repair from 2002 to 2010 at a single institution. Univariate analysis and multivariate Cox proportional hazards regression analysis were used to identify risk factors associated with mortality within 1 year after thoracic endovascular aortic repair.
RESULTS: During the study period, 282 patients underwent at least 1 thoracic endovascular aortic repair; index procedures included descending aortic repair (n = 189), hybrid arch repair (n = 55), and hybrid thoracoabdominal repair (n = 38). The 30-day/in-hospital mortality was 7.4% (n = 21) and the overall 1-year mortality was 19% (n = 54). Cardiopulmonary pathologies were the most common cause of nonperioperative 1-year mortality (22%, n = 12). Multivariate modeling demonstrated 3 variables independently associated with 1-year mortality: age older than 75 years (hazard ratio, 2.26; P = .005), aortic diameter greater than 6.5 cm (hazard ratio, 2.20; P = .007), and American Society of Anesthesiologists class 4 (hazard ratio, 1.85; P = .049). A baseline creatinine greater than 1.5 mg/dL (hazard ratio, 1.79; P = .05) and congestive heart failure (hazard ratio, 1.87; P = .08) were also retained in the final model. These 5 variables explained a large proportion of the risk of 1-year mortality (C statistic = 0.74).
CONCLUSIONS: Age older than 75 years, aortic diameter greater than 6.5 cm, and American Society of Anesthesiologists class 4 are independently associated with 1-year mortality after thoracic endovascular aortic repair. These clinical characteristics may help risk-stratify patients undergoing thoracic endovascular aortic repair and identify those unlikely to derive a long-term survival benefit from the procedure.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22698564     DOI: 10.1016/j.jtcvs.2012.05.005

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Results of thoracic endovascular aortic repair 6 years after United States Food and Drug Administration approval.

Authors:  Asad A Shah; Michael E Barfield; Nicholas D Andersen; Judson B Williams; Julie A Shah; Jennifer M Hanna; Richard L McCann; G Chad Hughes
Journal:  Ann Thorac Surg       Date:  2012-07-10       Impact factor: 4.330

2.  Results with an algorithmic approach to hybrid repair of the aortic arch.

Authors:  Nicholas D Andersen; Judson B Williams; Jennifer M Hanna; Asad A Shah; Richard L McCann; G Chad Hughes
Journal:  J Vasc Surg       Date:  2012-11-24       Impact factor: 4.268

3.  Frailty and risk in proximal aortic surgery.

Authors:  Asvin M Ganapathi; Brian R Englum; Jennifer M Hanna; Matthew A Schechter; Jeffrey G Gaca; Lynne M Hurwitz; G Chad Hughes
Journal:  J Thorac Cardiovasc Surg       Date:  2013-10-30       Impact factor: 5.209

4.  Thoracoabdominal aortic aneurysm: hybrid repair outcomes.

Authors:  G Chad Hughes; Nicholas D Andersen; Jennifer M Hanna; Richard L McCann
Journal:  Ann Cardiothorac Surg       Date:  2012-09

5.  Outcomes of open surgical repair of descending thoracic aortic disease.

Authors:  Won-Young Lee; Jae Suk Yoo; Joon Bum Kim; Sung-Ho Jung; Suk Jung Choo; Cheol Hyun Chung; Jae Won Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.